Epsilogen completes acquisition of TigaTx to create world’s leading pan-isotype cancer antibody company: London Tuesday, April 8, 2025, 10:00 Hrs [IST] Epsilogen, the global lea ...

Highlights The acquisition combines IgA antibody assets and expertise of Boston-based TigaTx with Epsilogen's assets and expertise in IgE to create the world's leading pan-isotype cancer antibody ...

A 43-year-old woman presented with 6 months of recurrent bilateral eye pain and redness alongside spontaneous urticaria.She ...

Epsilogen has acquired antibody developer TigaTx in a deal that collates work from the companies’ alternative antibody isotopes for cancer.

Looking ahead, Epsilogen sees the deal as giving it the option to “mix and match IgE, IgA and IgG functionality into a single antibody molecule.” “Such hybrid antibodies have the potential ...

Now, Epsilogen's portfolio can span antibodies which combine IgE and IgG functionality into a single ... two different antigens simultaneously, and IgA molecules with improved manufacturing ...

with sustained IgG and IgA antibody levels detected beyond 245 days and peripheral blood mononuclear cell (PBMC) responses persisting for at least 180 days post-vaccination. These findings build ...

Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces positive in-vivo proof-of-concept data for a powder-based intranasal vaccine candidate formulated with the AmorphOX technology.

Under normal conditions, "vaccines generate a response through pneumococcus-specific IgG antibodies. However, in patients with IgA deficiency, the lack of IgA reduces the vaccine's effectiveness," ...